微芯生物(688321.SH):公司目前約10億人民幣的資金儲備
格隆匯5月17日丨微芯生物(688321.SH)近日在接待機構投資者調研時表示,公司目前約10億人民幣的資金儲備,包括在手現金、銀行理財和已發行但尚未使用完畢的債券資金。預計未來兩年的研發投入與去年規模差不多。由於臨牀試驗是分階段進行的,資金的投入也是逐步增加的,這樣可以避免一次性大量資金的支出。公司注重提高資金使用效率,通過優化臨牀試驗設計和運營來控制成本。公司採取降本增效的策略,以確保在持續研發投入的同時,不會犧牲未來的成長潛力。公司也將持續提升經營質量,加快商業化進程,力爭在利潤端有更好表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.